Mechanism of action and pharmacokinetics of daprodustat

Daprodustat (Daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that has gradually attracted attention in recent years. The core mechanism of this drug is to prevent the degradation of hypoxia-inducible factor (HIF) by inhibiting the activity of prolyl hydroxylase (PHD), allowing HIF to stably exist in the body and exert its biological functions.

HIF is a type of transcription factor that is activated when oxygen supply is insufficient. It can regulate the expression of a variety of genes, including erythropoietin (EPO), iron transport-related proteins, and key enzymes in the heme synthesis pathway. In this way, daprostat can stimulate the body to naturally increase endogenous erythropoietin levels and improve chronic kidney disease-related anemia. Compared with traditional exogenous erythropoietin (ESA), this mechanism is closer to the physiological regulation mode of the human body, and therefore shows unique advantages in hemoglobin stability and iron utilization efficiency.

From the perspective of pharmacokinetic characteristics, daprostat is a small molecule compound and has good bioavailability after oral absorption. It is mainly metabolized by cytochrome P450 enzymes in the liver, especially related to the CYP2C8 pathway, which means that you need to pay attention to interactions with other drugs during use. Its moderate half-life supports a once-daily oral dosing regimen, which not only improves patient compliance but also facilitates long-term management. Compared with injectable ESAs, oral formulations significantly reduce the frequency of injections in dialysis centers or outpatient clinics, which is especially practical for patients with non-dialysis chronic kidney disease.

In terms of drug distribution, daprostat can quickly act on bone marrow erythroid precursor cells, promote red blood cell production, and also improve iron metabolism pathways. Specifically, it can downregulate the level of hepcidin (Hepcidin) in the liver, allowing the body to absorb and utilize iron more effectively, thereby balancing erythropoiesis and iron metabolism in anemia management.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat